- Home
- NA vs GALT Comparison
NA vs GALT Comparison
Compare NA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- GALT
- Stock Information
- Founded
- NA 2019
- GALT 2000
- Country
- NA China
- GALT United States
- Employees
- NA N/A
- GALT N/A
- Industry
- NA Semiconductors
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- GALT Health Care
- Exchange
- NA Nasdaq
- GALT Nasdaq
- Market Cap
- NA 77.6M
- GALT 83.5M
- IPO Year
- NA 2022
- GALT N/A
- Fundamental
- Price
- NA $5.94
- GALT $3.69
- Analyst Decision
- NA
- GALT Buy
- Analyst Count
- NA 0
- GALT 2
- Target Price
- NA N/A
- GALT $6.00
- AVG Volume (30 Days)
- NA 433.4K
- GALT 309.6K
- Earning Date
- NA 09-17-2025
- GALT 08-12-2025
- Dividend Yield
- NA N/A
- GALT N/A
- EPS Growth
- NA N/A
- GALT N/A
- EPS
- NA N/A
- GALT N/A
- Revenue
- NA $5,561,770.00
- GALT N/A
- Revenue This Year
- NA N/A
- GALT N/A
- Revenue Next Year
- NA N/A
- GALT N/A
- P/E Ratio
- NA N/A
- GALT N/A
- Revenue Growth
- NA N/A
- GALT N/A
- 52 Week Low
- NA $2.75
- GALT $0.73
- 52 Week High
- NA $31.48
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- NA 36.24
- GALT 75.28
- Support Level
- NA $6.55
- GALT $2.54
- Resistance Level
- NA $7.54
- GALT $3.75
- Average True Range (ATR)
- NA 0.89
- GALT 0.28
- MACD
- NA -0.21
- GALT 0.05
- Stochastic Oscillator
- NA 3.43
- GALT 83.87
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.